Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
Date:11/6/2009

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® ophthalmic solution on the first day following patent expiration. This strength of ketorolac is therapeutically equivalent to Acular® Ophthalmic Solution, 0.5%, from Allergan, Inc. Ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Acular® ophthalmic solution has annual sales of approximately $40 million in the US.

Acular® is a registered trademark of Allergan, Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
3. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
4. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
6. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
7. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
8. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
9. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
10. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
11. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 23, 2017 The global peripheral I.V. ... and it is expected to grow at a CAGR ... segment accounted for larger share in the global market ... various end users, the hospital segment accounted for the ... year. The global peripheral I.V. catheter market is witnessing ...
(Date:1/23/2017)... DUBLIN , Jan. 23, 2017 Endo ... Federal Trade Commission (FTC) today filed a joint motion ... of California seeking the entry ... Stipulated Order resolves all disputes between the FTC and ... into in connection with its Opana® ER and Lidoderm® ...
(Date:1/23/2017)... YORK , Jan. 23, 2017 MouthWatch LLC ... Camera was ranked as the best intraoral camera on ... taking the #2 spot overall. The #1 product was the ... said the MouthWatch intraoral camera was "…incredibly popular because it ... the camera has a small sticker price, it doesn,t sacrifice ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... “Speaking With God’s Voice”: ... God’s Voice” is the creation of published author, Louis A. Miraglia, a born-again believer, ... best to deliver God’s great, impactful Word. , “There is little doubt that ...
(Date:1/24/2017)... ... 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: an engaging ... to all Christians. “Mysteries Revealed On Speaking In Tongues” is the creation of published ... talk show located in Michigan. , “We need to partner with Jesus and ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink is now ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
(Date:1/24/2017)... Utah (PRWEB) , ... January 23, 2017 , ... The ... now) features a three-year outcome study on how outdoor behavioral healthcare (OBH) – also ... of distress and interpersonal difficulties while experiencing an increased sense of purpose both during ...
(Date:1/24/2017)... ... January 23, 2017 , ... Somnoware, a leading provider of ... centers to automatically connect and initialize all their devices with one click. This ... quickly installed on first use and then monitors device changes automatically. With this ...
Breaking Medicine News(10 mins):